Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

US President Donald Trump’s plan to drop a 200 per cent tariff bomb on Australian pharmaceuticals is set to “screw over” the ...

In the mid-1990s, my then-husband passed away from complications of HIV/AIDS. From the time he was diagnosed until he died, all of us, friends and family, but most of all, him, knew how it would end.

The report also provides a detailed analysis of the current Cancer cachexia marketed drugs and late-stage pipeline drugs. BROOKLYN, NY, UNITED STATES, July 14, 2025 /EINPresswire.com/ -- According to ...

When it comes to groundbreaking biotech advancements, Eric Faw Intellia is a name you might wanna keep an eye on. This ...

Kerala State Lotteries programme, the first of its kind in India, is a flagship initiative by the Government of Kerala, ...

Kerala State Lotteries programme, the first of its kind in India, is a flagship initiative by the Government of Kerala, ...

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...

Hemlibra safely reduces bleeding episodes in people with hemophilia A without inhibitors, per a review study that confirmed ...

Certain immune markers in the blood may help predict ITI response among hemophilia A patients given immune tolerance induction, a study found.

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for individuals aged 12 to <75 years living with hemophilia A or B with inhibitors.

Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later — 13-year follow-up shows stable factor IX expression and low bleeding rates ...